Premium
Initiation of universal tumor screening for L ynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice
Author(s) -
Cohen Stacey A.,
Laurino Mercy,
Bowen Deborah J.,
Upton Melissa P.,
Pritchard Colin,
Hisama Fuki,
Jarvik Gail,
Fichera Alessandro,
Sjoding Britta,
Bennett Robin L.,
Naylor Lorraine,
Jacobson Angela,
Burke Wylie,
Grady William M.
Publication year - 2016
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.29758
Subject(s) - lynch syndrome , medicine , referral , colorectal cancer , genetic testing , cancer , oncology , medical genetics , family medicine , dna mismatch repair , genetics , biology , gene
BACKGROUND Lynch syndrome confers a hereditary predisposition to colorectal and other cancers. Universal tumor screening (UTS) for Lynch syndrome is recommended by several professional societies, but the implementation can be complex. This article describes the evaluation, process development, and initiation of Lynch syndrome UTS at a tertiary referral cancer center. METHODS A multidisciplinary team developed the new process design. Issues in 5 themes were noted: timing, funding, second‐opinion patients, result processing, and the role of genetics providers. A committee approach was used to examine each issue for process‐improvement development. RESULTS The issues related to testing were addressed individually for the successful implementation of UTS at the institutional level. In the conventional‐care period, 9 of 30 cases (30%) received Lynch syndrome screening, and 4 cases were referred to medical genetics. During the 6 months following the implementation of UTS, 32 of 44 patients (73%) received Lynch syndrome screening. The 13 unscreened patients all had identified reasons for nonscreening (eg, financial limitations). Ten patients were referred to medical genetics, which identified no new cases of Lynch syndrome, but a low‐risk adenomatous polyposis coli ( APC ) variant was detected in 1 individual. CONCLUSIONS The implementation of effective Lynch syndrome UTS can feasibly alter practice at the institutional level. This experience with the assessment and management of issues relevant to the successful implementation of a new clinical care paradigm based on emerging technology has implications for the uptake of advances across molecular oncology into clinical practice, and this is highly relevant in the current era of rapidly evolving genomic technology. Cancer 2016;122:393–401. © 2015 American Cancer Society .